London (UK), February 19, 2024, 7:30 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announced promising results for its drug candidate VDA-1275 in multiple mouse cancer and human cellular organoid model of solid tumors. VDA-1275 showed statistically significant efficacy as a monotherapy, as well as synergistic effects in combination with two standard-of-care cancer treatments: sorafenib, a kinase inhibitor, and cisplatin, a widely used chemotherapy drug. The study also showed that VDA-1275 induced an immunologic response, inducing anti-tumor macrophages and memory T-cells, and inhibiting tumor-promoting macrophages. The company will present these findings on 28 February, at the Sachs 17th Annual European Life Sciences CEO Forum.

Read the rest here:
Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care...